Kaan Balta
About Kaan Balta
Kaan Balta is a Cellular Therapy Specialist at Bristol Myers Squibb in the Greater Toronto Area, specializing in treatments for multiple myeloma. He has a background in medical affairs and laboratory work, with degrees in Biomedical Discovery & Commercialization from McMaster University.
Title and Current Role
Kaan Balta is a Cellular Therapy Specialist currently working at Bristol Myers Squibb in the Greater Toronto Area. He began his tenure at Bristol Myers Squibb in July 2020. In his role, Balta specializes in cellular therapy for ABECMA, a treatment for multiple myeloma.
Previous Experience at Celgene
Before joining Bristol Myers Squibb, Kaan Balta worked at Celgene in Ontario, Canada. He served as a Medical Affairs Specialist from 2019 to 2020, a 10-month tenure, and also held a role as a Medical Affairs Intern in Hematology Oncology for 8 months in 2019. At Celgene, Balta contributed to therapeutic development for treatments like Revlimid and Pomalyst, both for multiple myeloma.
Experience at McMaster University
Kaan Balta's career includes significant time at McMaster University in Hamilton, Ontario. From 2017 to 2018, he was a Laboratory Assistant. Additionally, he served as a Community Advisor from 2015 to 2018, providing guidance and support to the university community over a period of three years.
Education and Academic Background
Kaan Balta has a strong academic foundation rooted in biomedical sciences. He earned a Master's degree in Biomedical Discovery and Commercialization from McMaster University in 2019. Prior to that, he completed his Bachelor of Health Sciences in Biomedical Discovery and Commercialization at the same institution in 2018. Before his university studies, he received a High School Diploma from the International Baccalaureate in 2014.
Specialization in Multiple Myeloma Therapies
Kaan Balta specializes in therapies for multiple myeloma, particularly cellular therapy for ABECMA. His expertise also extends to therapeutic development for other treatments such as Revlimid and Pomalyst. His work in these areas is focused on advancing treatment options and improving patient outcomes.